Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: An approach using behavioral tests battery

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 26, Issue 1, 2015, Pages 25-33

  Kurhe, Yeshwant ^a   Mahesh, Radhakrishnan ^a   Gupta, Deepali ^a   Thangaraj, Devadoss ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

5 HT3 antagonist; chronic unpredictable mild stress; oxidative stress; sucrose preference

Indexed keywords

(4 PHENYLPIPERAZIN 1 YL) (QUINOXALIN 2 YL) METHANONE; CATALASE; ESCITALOPRAM; GLUTATHIONE; NITRITE; SEROTONIN 3 ANTAGONIST; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG; (4-PHENYLPIPERAZIN-1-YL)(QUINOXALIN-2-YL)METHANONE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; PIPERAZINE DERIVATIVE; QUINOXALINE DERIVATIVE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CHRONIC STRESS; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FORCED SWIM TEST; IMMOBILITY; LIPID PEROXIDATION; LIPID PEROXIDATION ASSAY; LOCOMOTION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; MENTAL STRESS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPID PEROXIDATION; MALE; MICE; PIPERAZINES; QUINOXALINES; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; STRESS, PSYCHOLOGICAL; SUCROSE;

EID: 84920837985     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2013-0160     Document Type: Article

References (43)

1. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002;34:13-25.
2. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363-73.
3. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioral-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.
4. Fontella FU, Siqueria IR, Vasconcellos AP, Tabajara AS, Netto CA, Dalmaz C. Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem Res 2005;30:105-11.
5. Bhattacharya SK, Muruganandam AV. Adaptogenic activity of Withania somnifera: an experimental study using a rat model of chronic stress. Pharmacol Biochem Behav 2003;75:547-55.
6. Bilici M, Efe H, Koroglu MA, Uydu HA, Bekaroglu M, Deger O. Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 2001;64:43-51.
7. Deakin JF. Depression and 5-HT. Int Clin Psychopharmacol 1991;6:23-8.
8. Adell A, Castro A, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today 2005;10:578-85.
9. Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol 2007;101:143-50.
10. Greenshaw AJ, Silverstone H. The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Drugs 1997;53:20-39.
11. Faerber L, Drechsler S, Ladenburger S, Gschaidmeier WH, Fischer W. The neuronal 5-HT3 receptor network after 20 years of research-evolving concepts in management of pain and inflammation. Eur J Pharmacol 2007;560:1-8.
12. Eisensamer B, Rammes G, Gimpl G, Ferrari U, Hapfelmeier G, Rupprecht R. Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor. Mol Psychiatr 2003;8:994-1007.
13. Mahesh R, Devadoss T, Pandey DK, Bhatt S, Yadav SK. Design, synthesis and structure-activity relationship of novel quinoxalin-2-carboxamides as 5-HT3 receptor antagonists for the management of depression. Bioorg Med Chem Lett 2010;20:6773-6.
14. Mahesh R, Kumar B, Jindal A, Bhatt S, Devadoss T, Pandey DK. Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a), a novel 5-HT3 receptor antagonist: an investigation in behavior-based rodent models of depression. Ind J Pharmacol 2012;44:560-5.
15. Qing-Qiu M, Siu-Po I, Kam-Ming K, Sam-Hip T, Chun-Tao C. Peony glycosides produce antidepressant-like action in mice exposed to chronic unpredictable mild stress: effects on hypothalamic-pituitary-adrenal function and brain-derived neurotrophic factor. Prog Neuropsychopharmacol Biol 2009;33:1211-6.
16. Casarotto PC, Andreatini R. Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 2007;17:735-42.
17. Engeland CG, Kavaliers M, Ossenkopp KP. Sex differences in the effects of muramyl dipeptide and lipopolysaccharide on locomotor activity and the development of behavioral tolerance in rats. Pharmacol Biochem Behav 2003;74:433-47.
18. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 1977;229:327-36.
19. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressant drugs. Psychopharmacology 1985;85:367-70.
20. Rodgers RJ, Dalvi A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 1997;21:801-10.
21. Kumar B, Kuhad A, Chopra K. Neuropsychopharmacological effect of sesamol in unpredictable chronic mild stress model of depression: behavioral and biochemical evidences. Psychopharmacology 2011;214:819-28.
22. Wills ED. Mechanism of lipid peroxide formation in animal tissues. Biochem J 1996;99:667-76.
23. Koller A. Total serum protein. In: Kaplan LA, Pesce AJ, editors. Clinical chemistry - theory, analysis, and correlation. St. Louis: Mosby Company, 1984:1316-9.
24. Jollow DJ, Mitchell JR, Zampaglione N, Gillette JR. Bromo-benze induced liver necrosis: protective role of glutathione and evidence for 3,4-bromobenzenoxide as the hepatotoxic metabolite. Pharmacology 1974;11:151-69.
25. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15 N] nitrate in biological fluids. Anal Biochem 1982;126:131-8.
26. Claiborne A. Catalase activity. In: Greenwald RA, editor. Handbook of methods for oxygen radical research, 2nd ed. Boca Raton, FL: CRC Press, 1985:283-4.
27. Mishra HP, Fridovich I. The role of superoxide anion in the auto-oxidation of the epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;247:3170-5.
28. Willner P. The validity of animal models of depression. Psychopharmacology 1984;83:1-16.
29. Luo DD, An SC, Zhang X. Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res Bull 2008;77:8-12.
30. Li S, Wang C, Wang M, Li W, Matsumoto K, Tang Y. Antidepressant like effects of piperine in chronic mild stress treated mice and its possible mechanisms. Life Sci 2007;80:1373-81.
31. Rajkumar R, Mahesh R. The auspicious role of 5-HT3 receptors in depression: a probable neuronal target. J Psychopharmacol 2010;24:455-69.
32. Cryan JF, Valentino RJ, Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 2005;29: 547-69.
33. Strekalova T, Gorenkova N, Schunk E, Dolgov O, Bartsch D. Selective effects of citalopram in a mouse model of stressinduced anhedonia with a control for chronic stress. Behav Pharmacol 2006;17:271-87.
34. Bekris S, Antoniou K, Daskas S, Papadopoulou-Daifoti Z. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav Brain Res 2005;161:45-59.
35. Hogg S. A review of the validity and variability of the elevated plus maze as an animal model of anxiety. Pharmacol Biochem Behav 1996;54:21-30.
36. Liu J, Wang X, Mori A. Immobilization stress-induced antioxidant defence changes in rat plasma, effect of treatment with reduced glutathione. Int J Biochem 1994;26:511-7.
37. Liu J, Wang X, Shigenaga MK, Yeo HC, Mori A, Ames BN. Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats. FASEB J 1996;10:1532-8.
38. Matsumoto K, Yobimoto K, Huong NT, Abdel-Fattah M, Hien TV, Watanabe H. Psychological stress-induced enhancement of brain lipid peroxidation via nitric oxide systems and its modulation by anxiolytic and anxiogenic drugs in mice. Brain Res 1999;839:74-84.
39. Sunanda Rao BS, Raju TR. Restraint stress-induced alterations in the levels of biogenic amines, amino acids, and AChE activity in the hippocampus. Neurochem Res 2000;25:1547-52.
40. Torres IL, Gamaro GD, Vasconcellos AP, Silveira R, Dalmaz C. Effects of chronic restraint stress on feeding behavior and on monoamine levels in different brain structures in rats. Neurochem Res 2002;27:519-25.
41. Park JW, Youn YC, Kwon OS, Jang YY, Han ES, Lee CS. Protective effect of serotonin on 6-hydroxydopamine- and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem Int 2002;40:223-33.
42. Eren I, Nazroglu M, Demirda A, Celik O, Uguz AC, Altunbaak A, et al. Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 2007;32:497-505.
43. Eren I, Nazroglu M, Demirda A. Protective effects of lamotrigine, aripiprazole and escitalopram on depressioninduced oxidative stress in rat brain. Neurochem Res 2007;32:1188-95.